Results 21 to 30 of about 2,650 (185)

Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration. [PDF]

, 2021
The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age-related macular ...
Di Antonio, L., Eandi, C.M., Kilian, R., Montesel, A., Rispoli, M., Savastano, M.C.   +5 more
core   +5 more sources

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration

Scientific Reports, 2022
In this study we evaluated the effect of intravitreal brolucizumab injections on choroidal thickness in patients with neovascular age-related macular degeneration (nAMD) who previously showed an incomplete response to anti-vascular endothelial growth ...
Ki Woong Bae, Dong Ik Kim, Daniel Duck-Jin Hwang   +2 more
doaj   +1 more source

KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. [PDF]

, 2023
PURPOSE To report the 100-week outcomes from KESTREL and KITE. DESIGN Two phase 3, double-masked, active-controlled, randomized trials. METHODS Patients with diabetic macular edema (DME) were randomized 1:1:1 to brolucizumab 3 mg/6 mg ...
Agostini, Hansjuergen T, Bouillaud, Emmanuel, Brown, David M, Chang, Andrew, Dhoot, Dilsher S, Garweg, Justus G, Kovacic, Lidija, Laude, Augustinus, Regillo, Carl, Souied, Eric, Wachtlin, Joachim, Wang, Lixin, Wang, Ying, Wolf, Sebastian, Wykoff, Charles C   +14 more
core   +1 more source

Effect of Intravitreal Brolucizumab in the Treatment of Polypoidal Choroidal Vasculopathy With Foveal Lipid Exudation. [PDF]

, 2023
A 71-year-old woman with a history of blurred vision in her right eye for nearly two months came to our attention. A complete ophthalmological evaluation, including best-corrected visual acuity measurement, fundus examination, spectral-domain optical ...
Carta V, Lixi F, Peiretti E, Tatti F
core   +1 more source

Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data [PDF]

, 2020
Aim: To compare the treatment effect of brolucizumab, a novel anti-vascular endothelial growth factor therapeutic, with a putative placebo in patients with wet age-related macular degeneration.
Agostini, H., Bucher, F., Calvo, P., Clemens, A., Colafrancesco, V., Gaucher, D., Mulyukov, Z., Pigeolet, E., Tsilimbaris, M.   +8 more
core   +1 more source

Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation

American Journal of Ophthalmology Case Reports, 2022
Purpose: To describe angiographic features of a case of delayed-onset retinal vascular occlusion and intraocular inflammation (IOI) following brolucizumab intravitreal injection (IVI).
Sentaro Kusuhara, Kyung Woo Kim, Akiko Miki, Makoto Nakamura   +3 more
doaj   +1 more source

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. [PDF]

, 2022
PURPOSE To compare the efficacy and safety of brolucizumab with aflibercept in patients with diabetic macular edema (DME). DESIGN Double-masked, 100-week, multicenter, active-controlled, randomized trials.
Bandello, Francesco, Barranco, Jose Juan Escobar, Bouillaud, Emmanuel, Brown, David M, Dhoot, Dilsher, Emanuelli, Andrés, Figueira, João, Garweg, Justus, Guerard, Nicolas, Gupta, Vishali, Kovacic, Lidija, Liew, Gerald, Ngah, Nor Fariza, Souied, Eric, Tadayoni, Ramin, Tuli, Raman, Wang, Lixin, Wang, Ying, Wolf, Sebastian   +18 more
core   +1 more source

Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy

BMC Ophthalmology, 2022
Purpose To report the efficacy and safety of brolucizumab in the treatment of refractory serous pigment epithelial detachment (PED) secondary to polypoidal choroidal vasculopathy (PCV). Methods Twenty-six eyes of 26 patients were included.
Seung Wan Nam, Zeeyoon Byun, Don-Il Ham, Mingui Kong   +3 more
doaj   +1 more source

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

BMC Health Services Research, 2022
Background Age-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative abnormalities in the central retina (macula).
Nicola Ferrante, Daniela Ritrovato, Rossella Bitonti, Gianluca Furneri   +3 more
doaj   +1 more source

Guía de recomendaciones para el manejo de brolucizumab [PDF]

, 2022
Brolucizumab; Intraocular inflammation; Patient managementBrolucizumab; Inflamación intraocular; Manejo del pacienteBrolucizumab; Inflamació intraocular; Maneig del pacientPurpose: Brolucizumab, a new generation anti-VEGF, has demonstrated efficacy and ...
Adán, Alfredo, Figueroa, Marta, Fonollosa, Alex, Gallego-Pinazo, Roberto, López Gálvez, María Isabel, Sararols, Laura   +5 more
core   +1 more source